Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors

[1]  M. Barbieri,et al.  Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials , 2022, Frontiers in Cardiovascular Medicine.

[2]  G. Paolisso,et al.  Sodium-Glucose Cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. , 2022, Pharmacological research.

[3]  H. Sourij,et al.  Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis , 2022, Frontiers in Pharmacology.

[4]  Ying-Ying Chen,et al.  Blocking of SGLT2 to Eliminate NADPH-Induced Oxidative Stress in Lenses of Animals with Fructose-Induced Diabetes Mellitus , 2022, International journal of molecular sciences.

[5]  R. Marfella,et al.  Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry , 2022, Cardiovascular Diabetology.

[6]  I. Bure,et al.  Histone Modifications and Non-Coding RNAs: Mutual Epigenetic Regulation and Role in Pathogenesis , 2022, International journal of molecular sciences.

[7]  N. Bratina,et al.  The Role of Epigenetic Modifications in Late Complications in Type 1 Diabetes , 2022, Genes.

[8]  P. Light,et al.  Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. , 2022, Journal of molecular and cellular cardiology.

[9]  R. Coronel,et al.  Direct cardiac effects of SGLT2 inhibitors , 2022, Cardiovascular Diabetology.

[10]  O. Zakiyanov,et al.  Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes , 2022, International journal of molecular sciences.

[11]  C. Granger,et al.  TROPONIN ELEVATION AS A MANIFESTATION OF COVID-19 MYOCARDIAL INFLAMMATION ASSOCIATED WITH INCREASED MORTALITY , 2022, Journal of the American College of Cardiology.

[12]  Shenghua Zhou,et al.  Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism , 2022, Frontiers in Pharmacology.

[13]  E. Abdollahi,et al.  Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages. , 2022, European journal of pharmacology.

[14]  D. Torella,et al.  Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey , 2021, Frontiers in Cardiovascular Medicine.

[15]  G. Paolisso,et al.  Adiponectin Related Vascular and Cardiac Benefits in Obesity: Is There a Role for an Epigenetically Regulated Mechanism? , 2021, Frontiers in Cardiovascular Medicine.

[16]  G. Paolisso,et al.  Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. , 2021, Metabolism: clinical and experimental.

[17]  L. Dworkin,et al.  Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease , 2021, Frontiers in Endocrinology.

[18]  M. Nouri,et al.  Dapagliflozin protects H9c2 cells against injury induced by lipopolysaccharide via suppression of CX3CL1/CX3CR1 axis and NF-κB activity. , 2021, Current molecular pharmacology.

[19]  V. Salomaa,et al.  Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM/BiomarCaRE consortium , 2021, Cardiovascular Diabetology.

[20]  H. Sourij,et al.  Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[21]  G. Paolisso,et al.  Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment , 2021, Molecular metabolism.

[22]  N. Sarrafzadegan,et al.  How Are Epigenetic Modifications Related to Cardiovascular Disease in Older Adults? , 2021, International journal of molecular sciences.

[23]  G. Paolisso,et al.  SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies. , 2021, Pharmacological research.

[24]  H. Kim.  Epidemiology of cardiovascular disease and its risk factors in Korea. , 2021, Global health & medicine.

[25]  C. Liang,et al.  Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy , 2021, Frontiers in Pharmacology.

[26]  Joseph M Pappachan,et al.  Diabetic heart disease: A clinical update , 2021, World journal of diabetes.

[27]  D. Newby,et al.  Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure , 2021, Heart.

[28]  M. Salehi,et al.  Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017 , 2021, BMC Public Health.

[29]  Xiaojing Shi,et al.  Empagliflozin alleviates ethanol‐induced cardiomyocyte injury through inhibition of mitochondrial apoptosis via a SIRT1/PTEN/Akt pathway , 2021, Clinical and experimental pharmacology & physiology.

[30]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[31]  G. Paolisso,et al.  New insight in molecular mechanisms regulating SIRT6 expression in diabetes: Hyperglycaemia effects on SIRT6 DNA methylation , 2020, Journal of cellular physiology.

[32]  G. Paolisso,et al.  Incretin drugs effect on epigenetic machinery: New potential therapeutic implications in preventing vascular diabetic complications , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  Qingguo Lu,et al.  Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice , 2020, Diabetes.

[34]  S. Verma,et al.  Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure , 2020, Circulation. Heart failure.

[35]  L. Ghiadoni,et al.  The effects of dapagliflozin on systemic and renal vascular function display an epigenetic signature. , 2019, The Journal of clinical endocrinology and metabolism.

[36]  M. Nayak,et al.  A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. , 2019, Current pharmaceutical design.

[37]  H. Argani,et al.  Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis , 2019, Iranian journal of basic medical sciences.

[38]  H. Argani,et al.  Empagliflozin Attenuates Renal and Urinary Markers of Tubular Epithelial Cell Injury in Streptozotocin-induced Diabetic Rats , 2018, Indian Journal of Clinical Biochemistry.

[39]  N. Chattipakorn,et al.  Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors , 2018, Cardiovascular Diabetology.

[40]  I. Shimomura,et al.  Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes , 2018, Scientific Reports.

[41]  C. Indolfi,et al.  Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links , 2018, Front. Endocrinol..

[42]  A. Giaccari,et al.  Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date , 2017, Drug design, development and therapy.

[43]  D. Harrison,et al.  Sirt3 Impairment and SOD2 Hyperacetylation in Vascular Oxidative Stress and Hypertension , 2017, Circulation research.

[44]  J. Perez-polo,et al.  SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor , 2017, Cardiovascular Drugs and Therapy.

[45]  V. Mohan,et al.  Augmentation of histone deacetylase 3 (HDAC3) epigenetic signature at the interface of proinflammation and insulin resistance in patients with type 2 diabetes , 2016, Clinical Epigenetics.

[46]  J. Stamler,et al.  Inflammatory stimuli induce inhibitory S-nitrosylation of the deacetylase SIRT1 to increase acetylation and activation of p53 and p65 , 2014, Science Signaling.

[47]  M. Sarras,et al.  Parp Inhibition Prevents Ten-Eleven Translocase Enzyme Activation and Hyperglycemia-Induced DNA Demethylation , 2014, Diabetes.

[48]  A. El-Osta,et al.  Transcriptional regulation by the Set7 lysine methyltransferase , 2013, Epigenetics.

[49]  R. Kowluru,et al.  Epigenetic modification of Sod2 in the development of diabetic retinopathy and in the metabolic memory: role of histone methylation. , 2013, Investigative ophthalmology & visual science.

[50]  M. De Felici,et al.  Poly(ADP-ribosyl)ation Acts in the DNA Demethylation of Mouse Primordial Germ Cells Also with DNA Damage-Independent Roles , 2012, PloS one.

[51]  R. Tothill,et al.  Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. , 2011, Genome research.

[52]  J. Brachmann,et al.  Heart Failure and Arrhythmias , 1990, Springer Berlin Heidelberg.

[53]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..